These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 25408520)
1. Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. Takada Y; Tohyama T; Watanabe J J Hepatobiliary Pancreat Sci; 2015 Apr; 22(4):279-86. PubMed ID: 25408520 [TBL] [Abstract][Full Text] [Related]
2. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. Xu DW; Wan P; Xia Q World J Gastroenterol; 2016 Mar; 22(12):3325-34. PubMed ID: 27022214 [TBL] [Abstract][Full Text] [Related]
3. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. Cillo U; Giuliani T; Polacco M; Herrero Manley LM; Crivellari G; Vitale A World J Gastroenterol; 2016 Jan; 22(1):232-52. PubMed ID: 26755873 [TBL] [Abstract][Full Text] [Related]
4. Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Lai Q; Lerut JP Curr Opin Organ Transplant; 2014 Jun; 19(3):229-34. PubMed ID: 24811435 [TBL] [Abstract][Full Text] [Related]
5. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? Otto G; Schuchmann M; Hoppe-Lotichius M; Heise M; Weinmann A; Hansen T; Pitton MP J Hepatol; 2013 Aug; 59(2):279-84. PubMed ID: 23587474 [TBL] [Abstract][Full Text] [Related]
6. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672 [TBL] [Abstract][Full Text] [Related]
7. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective. Cheung TT; Ho CL; Lo CM; Chen S; Chan SC; Chok KS; Fung JY; Yan Chan AC; Sharr W; Yau T; Poon RT; Fan ST J Nucl Med; 2013 Feb; 54(2):192-200. PubMed ID: 23321459 [TBL] [Abstract][Full Text] [Related]
9. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852 [TBL] [Abstract][Full Text] [Related]
10. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Sharr WW; Chan SC; Lo CM Transplantation; 2014 Apr; 97 Suppl 8():S10-7. PubMed ID: 24849822 [TBL] [Abstract][Full Text] [Related]
15. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639 [TBL] [Abstract][Full Text] [Related]
16. Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma. Piardi T; Gheza F; Ellero B; Woehl-Jaegle ML; Ntourakis D; Cantu M; Marzano E; Audet M; Wolf P; Pessaux P Ann Surg Oncol; 2012 Jun; 19(6):2020-6. PubMed ID: 22179632 [TBL] [Abstract][Full Text] [Related]
17. Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. Song BG; Sinn DH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW; Kim JM; Joh JW; Choi GS Transplant Proc; 2020 Apr; 52(3):881-888. PubMed ID: 32115240 [TBL] [Abstract][Full Text] [Related]
18. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Taketomi A; Sanefuji K; Soejima Y; Yoshizumi T; Uhciyama H; Ikegami T; Harada N; Yamashita Y; Sugimachi K; Kayashima H; Iguchi T; Maehara Y Transplantation; 2009 Feb; 87(4):531-7. PubMed ID: 19307789 [TBL] [Abstract][Full Text] [Related]
19. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590 [TBL] [Abstract][Full Text] [Related]
20. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Soejima Y; Taketomi A; Yoshizumi T; Uchiyama H; Aishima S; Terashi T; Shimada M; Maehara Y Transplantation; 2007 Apr; 83(7):893-9. PubMed ID: 17460559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]